Comparative Pharmacology
Head-to-head clinical analysis: FOAMICON versus HEMSOL HC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FOAMICON versus HEMSOL HC.
FOAMICON vs HEMSOL-HC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FOAMICON is a topical antifungal agent that inhibits ergosterol synthesis by binding to fungal cytochrome P450 14α-demethylase, disrupting fungal cell membrane integrity.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to reduce inflammation and immune response.
Adults: 200 mg orally once daily, with or without food.
Intravenous: 100 mg hydralazine hydrochloride (equivalent to 80.5 mg hydralazine base) administered over 30 minutes, every 6 hours as needed, for a maximum of 48 hours. Oral: 10–50 mg every 6 hours, adjusted based on response.
None Documented
None Documented
Terminal elimination half-life 12-15 hours; clinically, steady-state achieved in ~3 days.
Terminal elimination half-life: 1.2-2.5 hours; clinically, dose adjustments needed in hepatic impairment due to prolonged clearance
Primarily renal (65% unchanged, 15% as inactive metabolites); biliary/fecal 20%.
Renal: >90% as unconjugated and conjugated metabolites; biliary/fecal: <10%
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid